Skip to content


Sovaldi (sofosbuvir) is a small molecule pharmaceutical. Sofosbuvir was first approved as Sovaldi on 2013-12-06. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Sovaldi's patents are valid until 2030-12-11 (FDA).
Trade Name Sovaldi
Common Name Sofosbuvir
Indication chronic hepatitis c, hepatitis c
Drug Class Phosphoro-derivatives; antivirals: RNA polymerase (NS5B) inhibitor
Get full access now